echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > JNNP: Anti-MOG antibody-related diseases - differences in clinical characteristics and prognostics in Japan and Germany

    JNNP: Anti-MOG antibody-related diseases - differences in clinical characteristics and prognostics in Japan and Germany

    • Last Update: 2020-12-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Myelin-less-protrusive glial glial glycogen (MOG) is the only expressed membrane protein on the surface of the central nervous system (CNS) and myelin, and is considered a possible autoantigen for central nervous system demyelination diseases such as acute spreading encephalospinal myelitis, especially in pediatric populations and atypical multiple sclerosis, optic spinal cord spectrum disorder (NMOSD) and isolated optic neuroneitis (ON).
    neuropathy associated with anti-myelin-less protrusive glial cell glycoprotein IgG (MOG-IgG) is increasingly considered a new type of neuroinflamed disease.
    study the regional and ethnic differences in the clinical characteristics of MOG-IgG-related diseases in patients in East Asia (Japan) and Caucasus (Germany).
    method: A total of 73 MOG IgG serum-positive MOGAD patients who met the MOG encephalomyelitis standard proposed by Jarius et al., 44 patients from the Japanese Center (37 from Chiba University Hospital and 7 from Saitama Medical Center) and 29 patients from the German Center (14 from the Clinical Research Center for Neurotherapy, The University of Berlin Medical College, 15 from the Institute of Clinical Neuroimmunism of the LMU Hospital in Munich).
    different approaches to each center, but all methods show a high degree of specificity and sensitivity.
    AQP4 IgG was negative for all patients who participated in the study.
    neurological disorders are divided into ON, spinal corditis, and encephalopathy (including post-brain syndrome, brain-dry syndrome, inter-brain syndrome, and brain syndrome).
    results: age and gender were similar, with the highest incidence of optic neuritis (61% in Japan and 58% in Germany).
    , however, the annual recurrence rate of Japanese patients (0.4 vs. 0.8, p=0.019; no recurrence, 64% vs 25%, p=0.002), at the last time The scale score for extended disability at the time of visit was low (1.0 vs. 2.0; p=0.008), although the follow-up period was similar compared to German patients (average 73.9 months vs 73.4 months).
    , the Japanese have more common brain syndromes (27 percent than 4 percent ;p to 0.021) and less spinal cord (21 percent to 50 percent ;p to 0.012).
    Japanese patients were more likely to receive long-term corticosteroid therapy (73%), while German patients were more likely to use lysioxid or other immunosuppressants (63%).
    conclusion: In MOG-IgG patients, the Japanese tend to have mild illness, while most German patients have relapsed processes and more frequent spinal corditis, which is found to be consistent with optic neural spinal cord disease spectrum disorders.
    although preventive treatment options vary widely, genetic and environmental factors may be important factors in determining clinical esother and disease activity.
    Liu J, Mori M, Zimmermann H, et al Anti-MOG antibody-associated disorders: s difference in clinical profiles and prognosis in Japan and German Journal of Neurology, Neurosurgery Psython Published Online First: 20 November 2020. doi:10.1136/jnnp-2020-324422MedSci Original Source: MedSci Original Copyright Notice: All notes on this website "Source: Met Medical" or "Source: MedSci Original" text, images and audio and video materials, copyrighted by Mace Medical, not authorized by any media Websites or individuals may not be reproduced, and the authorizing reprints must include "Source: Metz Medicine".
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.